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I
n a recent issue of Antimicrobial Agents and Chemotherapy, Reingewertz et al. (1)
report on sensitization of slow-growing, nontuberculous mycobacteria (NTM) to the
anti-tubercular drug isoniazid (INH) upon expression of Mycobacterium bovis KatG.
KatG functions as a catalase-peroxidase (2, 3) and activates INH, which then inhibits
InhA, an enzyme involved in mycolic acid synthesis (4). However, a surge in INH-
resistant Mycobacterium tuberculosis clinical isolates is jeopardizing the role of INH as a
first-line drug (5). In general, resistance to INH can be acquired by mutations in katG or,
less frequently, in the promoter region of inhA (6, 7). In the first case, KatG no longer
activates INH, while in the second case, a higher tolerance to the drug is conferred by
increased InhA expression (8).
The aim of the aforementioned study was to elucidate the differences between
KatG-dependent INH activation in mycobacteria and its effect on INH susceptibility,
focusing on the opportunistic pathogens Mycobacterium avium subsp. paratuberculosis
and Mycobacterium marinum (both NTM and naturally refractory to INH).
NTM are mycobacteria not belonging to theM. tuberculosis complex and encompass
both slowly and rapidly growing mycobacterial species (SGM and RGM) (9). As shown
by our colleagues and other groups (1, 10–12), NTM usually show an innate decreased
susceptibility toward INH. Within NTM, RGM have significantly higher INH MICs than
SGM (11–13). The reason for this increased resistance is likely the result of several
factors, including a failure to activate the prodrug, target-level mutations, differences in
the C-terminal domain of KatG (3), the reduction of intracellular concentration (by
means of efflux pumps or decreased permeability) (14), and/or the possible nonessen-
tiality of the mycolic acid synthesis pathway in NTM (12). However, essentiality has been
proven by identifying pyridomycin as a specific inhibitor of InhA preventing growth of
both M. tuberculosis (MIC  0.39 mg/liter) and NTM (M. marinum MIC  3.13 mg/liter)
(15).
In the context of NTM, no other mycobacteria have proven to be as resilient as the
emerging opportunistic pathogens from the Mycobacterium abscessus complex (16). As
members of the RGM (9), their intrinsic antibiotic resistance through drug- and target-
modifying enzymes (17) has rendered M. abscessus complex infections extremely
challenging to treat. Lengthy regimens on multiple drugs with severe side effects are
the norm (11, 13). KatG phylogeny pinpointed M. abscessus complex as being closer to
M. tuberculosis than rpoB-based phylogeny did (1). Alignment of KatGMabs with KatGMtb
shows that the most common INH resistance-conferring clinical M. tuberculosis
mutations (18) are absent in M. abscessus ATCC 19977 and sequence identity is high
(approximately 72%).
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Our research group has taken advantage of the resistance of M. abscessus complex
to INH in a manner similar to that used by Reingewertz and coworkers. In a proof-of-
concept study, we heterologously expressed KatGMtb in M. abscessus complex from a
pMV361 (19) attB-integrative vector containing an apramycin (APR) resistance cassette
for selection (aac). This allowed us to develop new tools for the genetic manipulation
of M. abscessus complex and to use INH as an effective counterselection marker for
allelic replacements (20–24), even if the MIC was well above achievable therapeutical
concentrations (MIC  32 mg/liter) (Fig. 1). Our observations are in strong agreement
with the work from Reingewertz et al., showing a drop in MIC of approximately 30-fold,
and are proof that INH susceptibility can be successfully exploited. However, the
comparatively high MIC of recombinant M. abscessus complex pMV361-aac-katG indi-
cates that besides poor KatG-dependent INH activation, other factors contribute to the
high level INH resistance of M. abscessus.
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